Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate

NCT00312013 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00312013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00312013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2006
Completion date
July 31, 2009
Enrollment
503 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

thrombosis, venous